4-amino-5-(naphthalen-2-ylmethyl)-3-mercapto-1,2,4-triazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-amino-5-(naphthalen-2-ylmethyl)-3-mercapto-1,2,4-triazole
• 英文别名: 4-amino-5-(naphthalen-2-ylmethyl)-4H-1,2,4-triazole-3-thiol；4-Amino-3-(naphthalen-2-ylmethyl)-1H-1,2,4-triazole-5(4H)-thione；4-amino-3-(naphthalen-2-ylmethyl)-1H-1,2,4-triazole-5-thione
• 化学式: C₁₃H₁₂N₄S
• mdl: MFCD11543224
• 分子量: 256.331
• InChiKey: JXOHQGQWPGSTAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  85.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-硝基苯氧乙酸 、 4-amino-5-(naphthalen-2-ylmethyl)-3-mercapto-1,2,4-triazole 在 4-二甲氨基吡啶 、 四丁基溴化铵 、 三氯氧磷 作用下， 以93%的产率得到3-(β-naphthylmethyl)-6-((4-nitrophenoxy)methyl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
  参考文献：
  名称：

  SAR studies on 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles as inhibitors of Mtb shikimate dehydrogenase for the development of novel antitubercular agents

  摘要：

  三唑噻二唑是一种具有较强抗结核活性的药物，对MtSD有适度的抑制作用，并且没有明显的细胞毒性。

  DOI：

  10.1039/c5ra19334f
• 作为产物：
  描述：

  2-萘-2-基乙酰肼 在 一水合肼 、 potassium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 生成 4-amino-5-(naphthalen-2-ylmethyl)-3-mercapto-1,2,4-triazole
  参考文献：
  名称：

  SAR studies on 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles as inhibitors of Mtb shikimate dehydrogenase for the development of novel antitubercular agents

  摘要：

  三唑噻二唑是一种具有较强抗结核活性的药物，对MtSD有适度的抑制作用，并且没有明显的细胞毒性。

  DOI：

  10.1039/c5ra19334f

文献信息

• 4-Amino-1,2,4-triazole-3-thione-derived Schiff bases as metallo-β-lactamase inhibitors
  作者：Laurent Gavara、Laurent Sevaille、Filomena De Luca、Paola Mercuri、Carine Bebrone、Georges Feller、Alice Legru、Giulia Cerboni、Silvia Tanfoni、Damien Baud、Giuliano Cutolo、Benoît Bestgen、Giulia Chelini、Federica Verdirosa、Filomena Sannio、Cecilia Pozzi、Manuela Benvenuti、Karolina Kwapien、Marina Fischer、Katja Becker、Jean-Marie Frère、Stefano Mangani、Nohad Gresh、Dorothée Berthomieu、Moreno Galleni、Jean-Denis Docquier、Jean-François Hernandez

  DOI：10.1016/j.ejmech.2020.112720

  日期：2020.12

  potent, they represented a promising basis for the development of broad-spectrum MBL inhibitors. Here, we synthesized and characterized a large number of 4-amino-1,2,4-triazole-3-thione-derived Schiff bases. Compared to the previous series, the presence of an aryl moiety at position 4 afforded an average 10-fold increase in potency. Among 90 synthetic compounds, more than half inhibited at least one

  产生金属β-内酰胺酶（MBL）的革兰氏阴性菌对β-内酰胺抗生素的耐药性代表着重大的医学威胁，并且迫切需要开发临床上有用的抑制剂。我们先前报道了MBL催化位点中的5个取代的4-氨基/ H-1,2,4-三唑-3-硫酮化合物的原始结合模式。此外，我们表明，尽管具有中等效力，但它们代表了广谱MBL抑制剂开发的有希望的基础。在这里，我们合成和表征了大量的4-氨基-1,2,4-三唑-3-硫酮衍生的席夫碱。与先前的系列相比，在4位上存在芳基部分可使效力平均提高10倍。在90种合成化合物中，超过一半的化合物抑制了至少六个被测MBL（L1，VIM-4，VIM-2，NDM-1，IMP-1，K i的值在μM至亚μM范围内。几种是广谱抑制剂，也可以抑制临床上最相关的VIM-2和NDM-1。活性化合物通常在位置5处包含卤代，双环芳基或酚基部分，以及在邻苯甲酸，2,4-二羟基苯基，对苄氧基苯基或3-（m-苯甲酰基）-
• INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US20170258805A1

  公开（公告）日：2017-09-14

  Compounds and salts thereof which are acyl-sulfonamides or certain carboxylic acids and which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include 2-aminothiazoles and triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 2-amino and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium , for example, M. tuberculosis and M. smegmatis and Klebsiella , for example, Klebsiella pneumoniae . Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.

  其酰基磺酰胺或某些羧酸的化合物及其盐，能够抑制微生物生长或减弱病原微生物的毒力，并且能够抑制UDP-半乳糖吡喃糖异构酶（UGM）。该发明的化合物包括2-氨基噻唑和三唑噻二嗪，特别是3,6,7-取代的7H-[1,2,4]三唑噻二嗪和其盐，以及2-氨基。抑制微生物病原体生长或减弱其毒力的方法包括结核分枝杆菌（例如结核分枝杆菌和平滑分枝杆菌）和克雷伯氏菌（例如肺炎克雷伯氏菌）等微生物病原体。抑制真核人类和动物病原体、真菌和线虫的方法，特别是治疗原核和真核病原体感染的方法，采用了该发明的化合物。
• 1,2,4-Triazole-3-thione Compounds as Inhibitors of Dizinc Metallo-β-lactamases
  作者：Laurent Sevaille、Laurent Gavara、Carine Bebrone、Filomena De Luca、Lionel Nauton、Maud Achard、Paola Mercuri、Silvia Tanfoni、Luisa Borgianni、Carole Guyon、Pauline Lonjon、Gülhan Turan-Zitouni、Julia Dzieciolowski、Katja Becker、Lionel Bénard、Ciaran Condon、Ludovic Maillard、Jean Martinez、Jean-Marie Frère、Otto Dideberg、Moreno Galleni、Jean-Denis Docquier、Jean-François Hernandez

  DOI：10.1002/cmdc.201700186

  日期：2017.6.21

  Metallo-β-lactamases (MBLs) cause resistance of Gram-negative bacteria to β-lactam antibiotics and are of serious concern, because they can inactivate the last-resort carbapenems and because MBL inhibitors of clinical value are still lacking. We previously identified the original binding mode of 4-amino-2,4-dihydro-5-(2-methylphenyl)-3H-1,2,4-triazole-3-thione (compound IIIA) within the dizinc active

  金属β-内酰胺酶（MBLs）引起革兰氏阴性细菌对β-内酰胺类抗生素的耐药性并引起人们的严重关注，因为它们可以使最后的碳青霉烯类药物失活，并且仍然缺乏具有临床价值的MBL抑制剂。我们之前确定了在其二嗪活性位点内4-氨基-2,4-二氢-5-（2-甲基苯基）-3H-1,2,4-三唑-3-硫酮（化合物IIIA）的原始结合模式。 L1 MBL。在这里，我们提出了L1与相应的非氨基化合物IIIB（1,2-二氢-5-（2-甲基苯基）-3H-1,2,4-三唑-3-硫酮）的配合物的晶体结构。出乎意料的是，IIIB的结合模式与IIIA相似，但相反。3D结构表明三唑-硫酮骨架适合结合二锌金属酶的催化位点。根据这些结果，我们合成了IIIA或IIIB的54个类似物。有19个显示的IC50值在微摩尔范围内，朝着五个代表性MBL（即L1，VIM-4，VIM-2，NDM-1和IMP-1）中的至少一个显示。其中五个对至少四
• Inhibitors of UDP-galactopyranose mutase
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US10080757B2

  公开（公告）日：2018-09-25

  Compounds and salts thereof which are acyl-sulfonamides or certain carboxylic acids and which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include 2-aminothiazoles and triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 2-amino and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.

  本发明的化合物及其盐类为酰基磺酰胺类或某些羧酸类，可抑制微生物生长或减弱病原微生物的毒力，并可抑制UDP-半乳糖吡喃糖突变酶（UGM）。本发明的化合物包括 2-氨基噻唑和三唑并噻二嗪，特别是 3,6,7-取代的-7H-[1,2,4]三唑并[3,4-b][1,3,4]噻二嗪及其 2-氨基和盐。抑制微生物病原体生长或减弱其毒性的方法，这些微生物病原体包括分枝杆菌（例如结核杆菌和烟曲霉菌）和克雷伯氏菌（例如肺炎克雷伯氏菌）。抑制真核人类和动物病原体，特别是真菌和线虫的方法。利用本发明化合物治疗原核和真核病原体感染的方法。
• Preliminary SAR and biological evaluation of antitubercular triazolothiadiazine derivatives against drug-susceptible and drug-resistant Mtb strains
  作者：Ziqiang Li、Xiaoguang Bai、Qi Deng、Guoning Zhang、Lei Zhou、Yishuang Liu、Juxian Wang、Yucheng Wang

  DOI：10.1016/j.bmc.2016.10.027

  日期：2017.1

  Following up the SAR study of triazolothiadiazoles for their antitubercular activities targeting Mt SD in our previous study, on the principle of scaffold hopping, the C3 and C6 positions of triazolothiadiazine were examined systematically to define a preliminary structure-activity relationship (SAR) with respect to biological activity. This study herein highlights the potential of two highly potent advanced leads 6c-3, 6g-3 and several other compounds with comparable potencies as promising new candidates for the treatment of TB (6c-3, MIC-H37Rv = 0.25 mu g/mL; MIC-MDRTB = 2.0 mu g/mL; MIC-RDRTB = 0.25 mu g/mL; Mt SD-IC50 = 86.39 mu g/mL; and 6g-3, MIC-H37Rv = 1.0 mu g/mL; MIC-MDRTB = 4.0 mu g/mL; MICRDRTB = 2.0 mu g/mL; Mt SD-IC50 = 73.57 mu g/mL). Compounds 6c-3 and 6g-3 possessed a para-nitro phenyl at the 6 position showed low Vero and HepG2 cells toxicity, turning out to be two excellent lead candidates for preclinical trials. In addition, in vitro Mt SD inhibitory assay indicates that Mt SD is at least one of the targets for their antitubercular activity. Thus, they may turn out to be promising multidrug-resistance- reversing agents. (C) 2016 Elsevier Ltd. All rights reserved.